New drug targets Gene-Mutated breast cancer in phase 2 trial
NCT ID NCT06840483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 study tests a drug called zelenectide pevedotin in 66 people with advanced breast cancer that has a specific gene change (NECTIN4 amplification). The study includes two groups: one with hormone receptor-positive/HER2-negative cancer and one with triple-negative breast cancer. The main goal is to see if the drug shrinks tumors, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zelenectide pevedotin (BT8009)
What this could lead to
If successful, this could provide a new treatment option for people with advanced breast cancer that has a specific genetic marker (NECTIN4 amplification).
What could go wrong
This is an early Phase 2 study with only 66 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Oncologica-Azienda Ospedaliero Universitaria delle Marche
Ancona, 60126, Italy
-
Compass Oncology - Rose Quarter Cancer Center
Portland, Oregon, 97227, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Hospital Beata Maria Ana
Madrid, 28007, Spain
-
Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Istituto Europeo di Oncologia
Milan, 20141, Italy
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS IRST
Meldola, Forli/Cesena, 47014, Italy
-
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York, 10065, United States
-
Oncopole Claudius Regaud
Toulouse, 31059, France
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (SKCCC)
Baltimore, Maryland, 21287, United States
-
Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Texas Oncology San Antonio
San Antonio, Texas, 78240, United States
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
UZ Leuven
Leuven, 3000, Belgium
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States